主页文献库搜索
Zoledronic acid (ZA) effectively inhibits cancer treatment-induced bone loss ...

Brufsky(A),Harker(W G),Beck(J T),Carroll(R... J Clin Oncol 0000-00-00

...mos in favor of upfront vs delayed ZA group. ZA was safe and well tolerated. Updated 12 mos BMD data on all pts will be ...

Assessment of fetal radiation dose during maternal sentinel lymph node mappin...

Montgomery(L),Dauer(L),Doddamane(I),Germai... J Clin Oncol 0000-00-00

...mos, 6 mos, and 9mos). It was assumed that the injection site remained in the breast until complete decay of the technet...

A single arm, multicenter, open label, phase II study of lapatinib as 2L trea...

Wülfing(C),Machiels(J-P),Richel(D),Grimm(M... J Clin Oncol 0000-00-00

...mos, respectively. At wk 8, 10 pts had some degree of cytoreduction; however, most was short-lived. One pt remains on st...

A phase II trial of gemcitabine plus capecitabine (GX) in patients with advan...

Tannir(N M),Jonasch(E),McMichael(C),Wang(X... J Clin Oncol 0000-00-00

...mos (95% CI 3.5-9.4). Median OS has not been reached yet (14+ mos). 14 pts have died of PD. 61 pts had interruption of t...

Long-term follow-up in patients with metastatic renal cell cancer not treated...

Chand(V K),Sidloski(J),Clamon(G),Hohl(R J) J Clin Oncol 0000-00-00

...mos. vs. 10 mos., p<.001).,Survivals of highly selected patients with metastatic renal cancer are similar whether they r...

Effects of skeletal complications on total medical care costs in patients wit...

Delea(T E),McKiernan(J M),Brandman(J),Sung... J Clin Oncol 0000-00-00

...mos [lung] to 15 mos [breast]). After matching for age, gender, and comorbidities using propensity score, there were 201...

The impact of neoadjuvant chemotherapy and surgery on quality of life (QL) in...

Gralla(R J),Edelman(M J),Detterbeck(F C),J... J Clin Oncol 0000-00-00

...mos post-op, 78% of patients rated their QL as stable or improved (95% CI: 64% - 92%). A subgroup (7 of 33 pts) reported...

Seven year update of an EORTC phase III trial of high dose intensity M-VAC ch...

Sternberg(C N),de Mulder(P H M),Schornagel... J Clin Oncol 0000-00-00

...mos (95% CI 7.6-12.2) vs M-VAC 8.1 mos (95% CI 7.0-9.9). (p=.017; HR=0.73; 95% CI 0.56 - 0.95). The median survival was ...

Hematologic and cytogenetic (CTG) response to lenalidomide (CC-5013) in patie...

List(A F),Dewald(G),Bennett(J),Giagounadis... J Clin Oncol 0000-00-00

...mosome 5q31 is the most common CTG abnormality in MDS characterized by TD-anemia and megakaryocyte dysplasia. In a phase...

Maximal peritonectomy plus intraperitoneal chemo-hyperthermia (IPCH) in patie...

Rebollo(J),Bretcha(P),Farre(J),Martin(M L)... J Clin Oncol 0000-00-00

5168 Background: For most patients (pts), peritoneal carcinomatosis has an ominous prognosis and chemotherapy gives some...

上一页 693 694 695 696 697 698 699 700 701 下一页 697 / 共 704

联系地址

山东省济南市章丘区文博路2号

齐鲁师范学院 genelibs生信实验室

山东省济南市高新区舜华路750号

大学科技园北区F座4单元2楼

电话: 0531-88819269

微信公众号

关注微信订阅号,实时查看信息,关注医学生物学动态。


商务邮箱

E-mail: [email protected]